Please assess the completion status of the following clinical trial:

Trial Title: Topical Avastin for Treatment of Corneal Neovascularization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, at least 18 years of age~* Clinical stable corneal neovascularization (as defined above)~* Ability to understand and provide informed consent to participate in this study and willingness to follow study instructions and likely to complete all required visits.~* All female patients of childbearing potential will be excluded. A female is considered to be of childbearing potential unless she is postmenopausal and without menses for 12 months or without a uterus and/or both ovaries.~Exclusion Criteria:~* Current or recent (≤ 1 month) systemic corticosteroid therapy or periocular corticosteroid injections to the study eye~* Current or recent (≤ 3 months) intravitreal drug injection to the study eye; recent (≤ 1 month) change in dose and frequency of topical steroids and/or non-steroidal anti-inflammatory agents~* Uncontrolled hypertension defined as systolic blood pressure of ≥ 150 mmHg or diastolic blood pressure of ≥ 90 mmHg; history of a thromboembolic event, including myocardial infarction or cerebral vascular accident~* Patients age 75 or older; history of renal abnormalities~* Recent (≤ 3 months ) or planned surgery~* History of coagulation abnormalities, including end stage liver disease or current anticoagulation medication other than aspirin (warfarin, heparin, enoxaparin, or similar anticoagulant agent)~* All female patients of childbearing potential (a female is considered to be of childbearing potential unless she is postmenopausal and without menses for 12 months or without a uterus and/or both ovaries)~* Any condition (including language barrier) that precludes patient's ability to comply with study requirements including completion of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Topical Avastin 1.0% (Type: EXPERIMENTAL): Each patient will receive topical Avastin in one eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).